

---

## BENCHMARKS FOR MEASURES INCLUDED IN THE PERFORMANCE YEAR 2015 QUALITY AND RESOURCE USE REPORTS

---

### CMS-Calculated Outcome Measures

PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation
CMS-1	Acute Conditions Composite*	6.90	5.44
	<i>Bacterial Pneumonia*</i>	9.96	8.73
	<i>Urinary Tract Infection*</i>	7.02	7.76
	<i>Dehydration*</i>	3.69	4.18
CMS-2	Chronic Conditions Composite*	54.56	25.83
	<i>Diabetes (composite of 4 indicators)*</i>	17.98	20.11
	<i>Chronic Obstructive Pulmonary Disease (COPD) or Asthma*</i>	76.29	47.75
	<i>Heart Failure*</i>	112.54	54.80
CMS-3	All-Cause Hospital Readmissions	15.32%	1.43%

Note: Lower performance rates indicate better performance. CMS-1, CMS-2, and CMS-3 are calculated by CMS using administrative claims data.

\* Rate per 1,000 beneficiaries

**Physician Quality Reporting System (PQRS) Measures**

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
<b>Effective Clinical Care</b>		-	-	-	-	-	-	-	-
1* (GPRO DM-2, CMS122v2)	Diabetes Mellitus (DM): Hemoglobin A1c Poor Control	28.44%	22.96%	X	X	X	X	X	X
2 (CMS163v2)	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	51.25%	23.38%	X	X	X	X	-	X
5 (CMS135v2)	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	83.01%	15.94%	-	X	X	X	-	X
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	89.48%	16.99%	X	X	-	X	-	X
7 (CMS145v2)	Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	88.37%	26.85%	-	X	X	-	-	X
8 (GPRO HF-6, CMS144v2)	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	86.35%	16.04%	-	X	X	X	X	X
9 (CMS128v2)	Anti-Depressant Medication Management	64.21%	27.32%	-	X	X	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
12 (CMS143v2)	Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation	95.95%	10.09%	X	X	X	-	-	X
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	93.40%	20.11%	X	X	-	-	-	X
18 (CMS167v2)	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	94.21%	17.65%	X	X	X	-	-	X
19 (CMS142v2)	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	86.55%	27.09%	X	X	X	-	-	X
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	85.92%	12.94%	X	X	-	-	-	X
31	Stroke and Stroke Rehabilitation: Venous Thromboembolism (VTE) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	82.95%	24.11%	X	X	-	-	-	X
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	81.61%	26.65%	X	X	-	-	-	X
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	84.73%	22.43%	-	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR	
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO		
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	78.61%	29.91%	X	X	-	-	-	X
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	73.26%	30.97%	X	X	-	-	-	X
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	44.32%	29.63%	X	X	-	X	-	X
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	39.15%	35.60%	X	X	-	-	-	X
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	55.19%	28.52%	X	X	-	-	-	X
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	98.71%	5.60%	X	X	-	X	-	X
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	88.59%	21.67%	X	X	-	X	-	X
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	54.91%	36.53%	X	X	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR	
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO		
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	92.74%	18.07%	X	X	-	-	-	X
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	66.79%	34.61%	X	X	-	X	-	X
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	92.35%	22.92%	X	X	-	X	-	X
53	Asthma: Pharmacologic Therapy for Persistent Asthma—Ambulatory Care Setting	95.48%	11.64%	-	X	-	X	-	X
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	94.52%	8.63%	X	X	-	-	-	X
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	93.95%	11.21%	X	X	-	-	-	X
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	94.75%	11.87%	X	X	-	-	-	X
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	91.66%	13.10%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
64 Asthma: Assessment of Asthma Control— Ambulatory Care Setting	67.54%	35.60%	-	X	-	X	-	X	
67 Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	97.01%	10.36%	X	X	-	-	-	X	
68 Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	97.62%	6.58%	X	X	-	-	-	X	
69 Hematology: Multiple Myeloma: Treatment with Bisphosphonates	92.86%	9.83%	X	X	-	-	-	X	
70 Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	97.32%	9.48%	X	X	-	-	-	X	
71 (CMS140v1) Breast Cancer: Hormonal Therapy for Stage IC— III C Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	87.01%	26.38%	X	X	X	X	-	X	
72 (CMS141v3) Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	85.95%	25.12%	X	X	X	X	-	X	

2014 PQRs Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
83 Hepatitis C: Confirmation of Hepatitis C Viremia	-	-	-	X	-	-	-	X
84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	95.53%	9.44%	-	X	-	X	-	X
85 Hepatitis C: Hepatitis C Virus (HCV) Genotype Testing Prior to Treatment	82.88%	22.49%	-	X	-	X	-	X
87 Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4-12 Weeks After Initiation of Treatment	68.68%	35.09%	-	X	-	X	-	X
91 Acute Otitis Externa (AOE): Topical Therapy	84.77%	23.52%	X	X	-	-	-	X
99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	96.31%	11.66%	X	X	-	-	-	X
100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	95.25%	17.30%	X	X	-	-	-	X
104 Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	96.12%	8.29%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
106	Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity	92.42%	19.63%	X	X	-	-	-	X
107 (CMS161v2)	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment	85.82%	26.96%	X	X	X	-	-	X
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	89.03%	22.79%	X	X	-	X	-	X
111 (GPRO PREV-8, CMS127v2)	Preventive Care and Screening: Pneumococcal Vaccination for Older Adults	50.19%	30.49%	X	X	X	X	X	X
112 (GPRO PREV-5, CMS125v2)	Preventive Care and Screening: Breast Cancer Screening	-	-	X	X	X	X	X	X
113 (GPRO PREV-6, CMS130v2)	Preventive Care and Screening: Colorectal Cancer Screening	47.54%	31.34%	X	X	X	X	X	X
117 (CMS131v2)	Diabetes Mellitus (DM): Dilated Eye Exam	85.69%	27.54%	X	X	X	X	-	X
118 (GPRO CAD-7)	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVSD) (LVEF < 40%)	72.74%	19.16%	-	X	-	-	X	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
119 (CMS134v2)	Diabetes Mellitus (DM): Medical Attention for Nephropathy	76.04%	22.98%	X	X	X	X	-	X
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	57.93%	30.49%	X	X	-	X	-	X
122	Adult Kidney Disease: Blood Pressure Management	69.17%	33.41%	X	X	-	X	-	X
123*	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA)— Hemoglobin Level > 12.0 g/dL	7.92%	16.26%	X	X	-	X	-	X
126	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Peripheral Neuropathy— Neurological Evaluation	59.53%	38.05%	-	X	-	-	-	X
127	Diabetes Mellitus (DM): Diabetic Foot and Ankle Care, Ulcer Prevention— Evaluation of Footwear	70.40%	35.73%	-	X	-	-	-	X
137	Melanoma: Continuity of Care—Recall System	88.09%	24.77%	-	X	-	-	-	X
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	87.50%	25.07%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	65.33%	36.96%	X	X	-	-	-	X
149	Back Pain: Physical Exam	87.12%	25.89%	-	-	-	X	-	X
150	Back Pain: Advice for Normal Activities	79.93%	32.55%	-	-	-	X	-	X
151	Back Pain: Advice Against Bed Rest	73.88%	36.04%	-	-	-	X	-	X
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	91.41%	10.53%	-	X	-	X	-	X
160 (CMS52v2)	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	-	-	-	X	X	X	-	X
163 (CMS123v2)	Diabetes Mellitus (DM): Foot Exam	57.11%	36.91%	X	X	X	X	-	X
164*	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	4.91%	5.85%	-	X	-	X	-	X
165*	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	67.87%	13.88%	-	X	-	X	-	X
166*	Coronary Artery Bypass Graft (CABG): Stroke	1.98%	4.81%	-	X	-	X	-	X
167*	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	3.89%	5.31%	-	X	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
168* Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration	2.76%	3.80%	-	X	-	X	-	X
169 Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	93.75%	15.83%	-	X	-	X	-	X
170 Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	97.27%	4.88%	-	X	-	X	-	X
171 Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	91.45%	11.14%	-	X	-	X	-	X
172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	91.68%	17.73%	X	X	-	-	-	X
176 Rheumatoid Arthritis (RA): Tuberculosis Screening	78.46%	34.30%	-	X	-	X	-	X
177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	95.94%	13.89%	-	X	-	X	-	X
178 Rheumatoid Arthritis (RA): Functional Status Assessment	80.16%	29.57%	-	X	-	X	-	X
179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	82.52%	29.47%	-	X	-	X	-	X
187 Stroke and Stroke Rehabilitation: Thrombolytic Therapy	-	-	-	X	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
191 (CMS133v2)	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	66.54%	32.95%	-	X	X	X	-	X
194	Oncology: Cancer Stage Documented	79.51%	28.80%	X	X	-	X	-	X
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	84.30%	20.15%	X	X	-	-	-	X
197 (GPRO CAD-2)	Coronary Artery Disease (CAD): Lipid Control	72.51%	21.99%	-	X	-	X	X	X
198	Heart Failure (HF): Left Ventricular Ejection Fraction (LVEF) Assessment	80.85%	24.19%	-	X	-	X	-	X
204 (GPRO IVD-2, CMS164v2)	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	79.60%	25.04%	X	X	X	X	X	X
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis	59.10%	31.60%	-	X	-	X	-	X
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	66.60%	29.51%	-	X	-	-	-	X
231	Asthma: Tobacco Use: Screening—Ambulatory Care Setting	80.59%	33.15%	X	X	-	X	-	X
232	Asthma: Tobacco Use: Intervention—Ambulatory Care Setting	78.17%	27.98%	X	X	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
233 Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	-	-	-	X	-	-	-	X	
236 (GPRO HTN-2, CMS165v2) Hypertension (HTN): Controlling High Blood Pressure	69.03%	14.92%	X	X	X	X	X	X	
241 (GPRO IVD-1, CMS182v3) Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (<100 mg/dL)	51.53%	19.77%	X	X	X	X	X	X	
242 Coronary Artery Disease (CAD): Symptom Management	91.47%	18.93%	-	X	-	X	-	X	
243 Cardiac Rehabilitation Patient Referral from an Outpatient Setting	-	-	-	X	-	-	-	X	
245 Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	98.68%	9.38%	X	X	-	-	-	X	
246 Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	98.31%	6.87%	X	X	-	-	-	X	
247 Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	96.48%	14.05%	X	X	-	-	-	X	

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR	
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO		
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	94.11%	16.49%	X	X	-	-	-	X
249	Barrett's Esophagus	98.79%	6.76%	X	X	-	-	-	X
250	Radical Prostatectomy Pathology Reporting	94.45%	15.79%	X	X	-	-	-	X
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	99.32%	4.82%	X	X	-	-	-	X
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	-	-	X	X	-	-	-	X
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	-	-	X	X	-	-	-	X
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	-	-	-	X	-	-	-	X
263	Preoperative Diagnosis of Breast Cancer	84.37%	25.26%	X	X	-	-	-	X
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	-	-	-	X	-	-	-	X
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	95.15%	14.89%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR	
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO		
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	91.56%	20.81%	X	X	-	-	-	X
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	-	-	X	X	-	-	-	X
269	Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented	94.15%	14.92%	-	-	-	X	-	X
270	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy	-	-	-	-	-	X	-	X
271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury—Bone Loss Assessment	-	-	-	-	-	X	-	X
272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization	68.47%	31.99%	-	-	-	X	-	X
273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization	45.93%	30.40%	-	-	-	X	-	X
274	Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	97.89%	9.92%	-	-	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					Measures Group	GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR					
275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	71.18%	27.44%	-	-	-	X	-	X	
276	Sleep Apnea: Assessment of Sleep Symptoms	97.76%	8.24%	-	-	-	X	-	X	
277	Sleep Apnea: Severity Assessment at Initial Diagnosis	97.11%	10.06%	-	-	-	X	-	X	
278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed	98.37%	7.64%	-	-	-	X	-	X	
279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy	94.92%	14.43%	-	-	-	X	-	X	
281 (CMS149v2)	Dementia: Cognitive Assessment	94.65%	17.30%	-	-	X	X	-	X	
282	Dementia: Functional Status Assessment	94.77%	14.48%	-	-	-	X	-	X	
283	Dementia: Neuropsychiatric Symptom Assessment	92.13%	17.61%	-	-	-	X	-	X	
284	Dementia: Management of Neuropsychiatric Symptoms	86.98%	24.28%	-	-	-	X	-	X	
285	Dementia: Screening for Depressive Symptoms	90.79%	19.04%	-	-	-	X	-	X	

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					Measures Group	GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR					
287	Dementia: Counseling Regarding Risks of Driving	73.25%	36.75%	-	-	-	X	-	X	
288	Dementia: Caregiver Education and Support	83.69%	27.16%	-	-	-	X	-	X	
289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review	97.66%	8.44%	-	-	-	X	-	X	
290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment	92.10%	18.08%	-	-	-	X	-	X	
291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment	94.95%	13.05%	-	-	-	X	-	X	
292	Parkinson's Disease: Querying about Sleep Disturbances	87.76%	23.32%	-	-	-	X	-	X	
293	Parkinson's Disease: Rehabilitative Therapy Options	87.17%	23.44%	-	-	-	X	-	X	
294	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed	96.47%	13.53%	-	-	-	X	-	X	
295	Hypertension (HTN): Appropriate Use of Aspirin or Other Antithrombotic Therapy	73.10%	23.94%	-	-	-	X	-	X	
296	Hypertension (HTN): Complete Lipid Profile	91.90%	14.63%	-	-	-	X	-	X	

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					Measures Group	GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR					
297	Hypertension (HTN): Urine Protein Test	77.46%	25.64%	-	-	-	X	-	X	
298	Hypertension (HTN): Annual Serum Creatinine Test	95.39%	10.69%	-	-	-	X	-	X	
299	Hypertension (HTN): Diabetes Mellitus Screening Test	92.79%	14.45%	-	-	-	X	-	X	
300	Hypertension (HTN): Blood Pressure Control	88.21%	14.04%	-	-	-	X	-	X	
301	Hypertension (HTN): Low Density Lipoprotein (LDL- C) Control	80.16%	19.32%	-	-	-	X	-	X	
302	Hypertension (HTN): Dietary and Physical Activity Modifications Appropriately Prescribed	83.16%	23.90%	-	-	-	X	-	X	
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	66.44%	41.00%	-	X	-	X	-	X	
305 (CMS137v2)	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	-	-	-	-	X	-	-	X	
309 (CMS124v2)	Cervical Cancer Screening	-	-	-	-	X	-	-	X	
311 (CMS126v2)	Use of Appropriate Medications for Asthma	-	-	-	-	X	-	-	X	

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
316 (CMS61v3 and CMS64v3)	-	-	-	-	X	-	-	X	
325	-	-	-	X	-	-	-	X	
327	-	-	X	X	-	-	-	X	
328*	-	-	X	X	-	-	-	X	
329*	-	-	-	X	-	-	-	X	
330*	-	-	-	X	-	-	-	X	
331*	71.59%	24.94%	-	X	-	-	-	X	

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR	
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO		
332	Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Patients with Acute Bacterial Sinusitis	41.92%	17.98%	-	X	-	-	-	X
337	Tuberculosis Prevention for Psoriasis and Psoriatic Arthritis Patients on a Biological Immune Response Modifier	71.77%	32.86%	-	X	-	-	-	X
338	HIV Viral Load Suppression	90.18%	7.16%	-	X	-	X	-	X
339	Prescription of HIV Antiretroviral Therapy	96.57%	7.28%	-	X	-	X	-	X
343	Screening Colonoscopy Adenoma Detection Rate	39.44%	16.86%	-	X	-	-	-	X
344	Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)	-	-	-	X	-	-	-	X
345*	Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS)	-	-	-	X	-	-	-	X
346*	Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Endarterectomy (CEA)	-	-	-	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
347* Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital	-	-	-	X	-	-	-	X	
348* HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate	-	-	-	X	-	-	-	X	
349 Optimal Vascular Care Composite	-	-	-	X	-	-	-	X	
354* Anastomotic Leak Intervention	0.27%	0.80%	-	-	-	X	-	X	
355* Unplanned Reoperation within the 30 Day Postoperative Period	1.45%	3.49%	-	-	-	X	-	X	
356* Unplanned Hospital Readmission within 30 Days of Principal Procedure	2.11%	3.74%	-	-	-	X	-	X	
357* Surgical Site Infection (SSI)	1.54%	4.73%	-	-	-	X	-	X	
365 (CMS148v2) Hemoglobin A1c Test for Pediatric Patients	-	-	-	-	X	-	-	X	
366 (CMS136v3) ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication	-	-	-	-	X	-	-	X	
367 (CMS169v2) Bipolar Disorder and Major Depression: Appraisal for Alcohol or Chemical Substance Use	-	-	-	-	X	-	-	X	

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	QCDR
368 (CMS62v2)	HIV/AIDS: Medical Visit	-	-	-	-	X	-	-	X
369 (CMS158v2)	Pregnant Women that Had HBsAg Testing	-	-	-	-	X	-	-	X
370 (CMS159v2)	Depression Remission at Twelve Months	-	-	-	-	X	-	-	X
371 (CMS160v2)	Depression Utilization of the PHQ-9 Tool	-	-	-	-	X	-	-	X
373 (CMS65v3)	Hypertension: Improvement in Blood Pressure	-	-	-	-	X	-	-	X
378* (CMS75v2)	Children Who Have Dental Decay or Cavities	-	-	-	-	X	-	-	X
379 (CMS74v3)	Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists	-	-	-	-	X	-	-	X
381 (CMS77v2)	HIV/AIDS: RNA Control for Patients with HIV	-	-	-	-	X	-	-	X
Composite Measures	-	-	-	-	-	-	-	-	-
-	Diabetes Mellitus (DM): Composite (All or Nothing Scoring)	26.32%	10.65%	-	-	-	-	X	X
(GPRO DM-13)	Diabetes Mellitus (DM): High Blood Pressure Control	70.06%	10.02%	-	-	-	-	X	X
(GPRO DM-14)	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control	58.50%	10.72%	-	-	-	-	X	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options				GPRO Web Interface/ACO	QCDR
				Claims	Registry	EHR	Measures Group		
(GPRO DM-15)	Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	70.67%	10.02%	-	-	-	-	X	X
(GPRO DM-16)	Diabetes Mellitus (DM): Daily Aspirin or Antiplatelet Medication Use for Patients with Diabetes and Ischemic Vascular Disease (IVD)	80.23%	17.26%	-	-	-	-	X	X
(GPRO DM-17)	Diabetes Mellitus (DM): Tobacco Non-Use	76.43%	17.66%	-	-	-	-	X	X
-	Coronary Artery Disease (CAD): Composite (All or Nothing Scoring)	68.99%	15.31%	-	-	-	-	X	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
AAAAI 1	Asthma: Pharmacologic Therapy for Persistent Asthma	-	-	-	-	-	-	-	X
AAAAI 2	Asthma: Assessment of Asthma Control	-	-	-	-	-	-	-	X
AAAAI 8	Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergy Immunotherapy for at Least One Year	-	-	-	-	-	-	-	X
AAAAI 11	Asthma Assessment and Classification	-	-	-	-	-	-	-	X
AAAAI 12	Lung Function/Spirometry Evaluation	-	-	-	-	-	-	-	X
ACR 1	Disease Activity Measurement for Patients with Rheumatoid Arthritis (RA)	-	-	-	-	-	-	-	X
ACR 2	Functional Status Assessment for Patients with Rheumatoid Arthritis (RA)	-	-	-	-	-	-	-	X
ACR 3	Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapy for Active Rheumatoid Arthritis (RA)	-	-	-	-	-	-	-	X
ACR 5	Glucocorticosteroids and Other Secondary Causes	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
ACCFocus 9*	Ratio: Initial Evaluations to Post Procedure/Follow-Up Evaluations with Cardiac Stress Imaging	-	-	-	-	-	-	-	X
ACCFocus 10*	Ratio: Initial Evaluations with Cardiac Stress Imaging for Symptomatic Patients to Initial Evaluations for Asymptomatic Patients	-	-	-	-	-	-	-	X
ACCPin 1	Hypertension: Blood Pressure Management	-	-	-	-	-	-	-	X
ACRad 1	CT Colonography True Positive Rate	-	-	-	-	-	-	-	X
ACRad 3	Screening Mammography Cancer Detection Rate (CDR)	-	-	-	-	-	-	-	X
ACRad 4	Screening Mammography Invasive Cancer Detection Rate (ICDR)	-	-	-	-	-	-	-	X
ACRad 6	Screening Mammography Positive Predictive Value 2 (PPV2—Biopsy Recommended)	-	-	-	-	-	-	-	X
ACRad 7	Screening Mammography Node Negativity Rate	-	-	-	-	-	-	-	X
ACRad 8	Screening Mammography Minimal Cancer Rate	-	-	-	-	-	-	-	X
AGACCSSR 2	Colonoscopy Assessment (Cecum Reached) – Cecal Intubation / Depth of Intubation	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
AGADHRPR 2 Colonoscopy Assessment (Cecum Reached) – Cecal Intubation / Depth of Intubation	-	-	-	-	-	-	-	X
ASBS 1 Surgeon Assessment for Hereditary Cause of Breast Cancer	-	-	-	-	-	-	-	X
AQI 5 Composite Anesthesia Safety	-	-	-	-	-	-	-	X
CDR 1 Process Measure: Adequate Off-Loading of Diabetic Foot Ulcers at Each Visit	-	-	-	-	-	-	-	X
CDR 4 Diabetic Foot & Ankle Care: Comprehensive Diabetic Foot Examination	-	-	-	-	-	-	-	X
CDR 5 Process Measure: Adequate Compression at Each Visit for Patients with Venous Leg Ulcers (VLU)	-	-	-	-	-	-	-	X
CDR 8 Appropriate Use of Hyperbaric Oxygen Therapy for Patients with Diabetic Foot Ulcers	-	-	-	-	-	-	-	X
CDR 9 Appropriate use of Cellular or Tissue Based Products (CTP) for Patients Aged 18 Years or Older with a Diabetic Foot Ulcer (DFU) or Venous Leg Ulcer (VLU)	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
CDR 10	Process Measure: Vascular Assessment of Patients with Chronic Leg Ulcers	-	-	-	-	-	-	-	X
CDR 11	Process Measure: Wound Bed Preparation through Debridement of Necrotic or Non-Viable Tissue	-	-	-	-	-	-	-	X
GIQIC 1	Adenoma Detection Rate	-	-	-	-	-	-	-	X
GIQIC 2	Adequacy of Bowel Preparation	-	-	-	-	-	-	-	X
GIQIC 3	Photo Documentation of the Cecum (also known as Cecal Intubation Rate)—All Colonoscopies	-	-	-	-	-	-	-	X
GIQIC 4	Photo Documentation of the Cecum (also known as Cecal Intubation Rate)—Screening Colonoscopies	-	-	-	-	-	-	-	X
GIQIC 9	Documentation of History and Physical Rate—Colonoscopy	-	-	-	-	-	-	-	X
ICLOPS 12*	Cholecystectomy Outcomes after 90 Days	-	-	-	-	-	-	-	X
ICLOPS 13*	Unexpected Outcomes for Breast Cancer Surgery	-	-	-	-	-	-	-	X
ICLOPS 14*	Post-Operative Sepsis Rate	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
MBSAQIP 1* Risk Standardized Rate of Patients Who Experienced a Post-Operative Complication within 30 Days Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	X
MBSAQIP 4* Risk Standardized Rate of Patients Who Experienced an Anastomotic/Staple Line Leak within 30 Days Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
MBSAQIP 5* Risk Standardized Rate of Patients Who Experienced a Bleeding/Hemorrhage Event Requiring Transfusion, Intervention/Operation, or Readmission within 30 Days Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	-	X
MBSAQIP 6* Risk Standardized Rate of Patients Who Experienced a Post-Operative Surgical Site Infection (SSI) (Superficial Incisional, Deep Incisional, or Organ/Space SSI) within 30 Days Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
MBSAQIP 7* Risk Standardized Rate of Patients Who Experienced Post-Operative Nausea, Vomiting or Fluid/Electrolyte/Nutritional Depletion within 30 Days Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	X
MBS 4 MBSC Venous Thromboembolism Prophylaxis Adherence Rates for Perioperative Care	-	-	-	-	-	-	-	X
MBS 5 MBSC Venous Thromboembolism Prophylaxis Adherence Rates for Postoperative Care	-	-	-	-	-	-	-	X
MBS 6 MBSC Venous Thromboembolism Prophylaxis Adherence Rates for Post-Discharge Care	-	-	-	-	-	-	-	X
MUSIC 2* Unplanned Hospital Admission within 30 Days of TRUS Biopsy	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
MUSIC 4 Prostate Cancer: Proportion of Patients with Low-Risk Prostate Cancer Receiving Active Surveillance	-	-	-	-	-	-	-	-	X
MUSIC 5* Prostate Cancer: Percentage of Prostate Cancer Cases with a Length of Stay > 2 Days	-	-	-	-	-	-	-	-	X
MUSIC 6* Unplanned Hospital Readmission within 30 Days of Radical Prostatectomy	-	-	-	-	-	-	-	-	X
NOF 1 Laboratory Investigation for Secondary Causes of Fracture	-	-	-	-	-	-	-	-	X
NOF 4 Osteoporosis Management in Women Who Had a Fracture	-	-	-	-	-	-	-	-	X
NOF 5 Osteoporosis Testing in Older Women	-	-	-	-	-	-	-	-	X
NOF 6* Hip Fracture Mortality Rate (IQI 19)	-	-	-	-	-	-	-	-	X
NOF 7 Osteoporosis: Percentage of Patients, Regardless of Age, with a Diagnosis of Osteoporosis Who Are Either Receiving Both Calcium and Vitamin D or Had Documented Counseling Regarding Both Calcium and Vitamin D Intake, and Exercise at Least Once within 12 Months	-	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
NOF 8	Osteoporosis: Percentage of Patients Aged 50 Years and Older with a Diagnosis of Osteoporosis Who Were Prescribed Pharmacologic Therapy within 12 Months	-	-	-	-	-	-	-	X
ONSQIR 1	Symptom Assessment	-	-	-	-	-	-	-	X
ONSQIR 2	Intervention for Psychosocial Distress	-	-	-	-	-	-	-	X
ONSQIR 3	Intervention for Fatigue	-	-	-	-	-	-	-	X
ONSQIR 4	Intervention for Sleep-Wake Disturbance	-	-	-	-	-	-	-	X
ONSQIR 5	Assessment for Chemotherapy Induced Nausea and Vomiting	-	-	-	-	-	-	-	X
ONSQIR 6	Education on Neutropenia Precautions	-	-	-	-	-	-	-	X
ONSQIR 7	Post-Treatment Symptom Assessment	-	-	-	-	-	-	-	X
ONSQIR 8	Post-Treatment Symptom Intervention	-	-	-	-	-	-	-	X
ONSQIR 9	Post-Treatment Education	-	-	-	-	-	-	-	X
OQIC 10*	PET Utilization in Breast Cancer Surveillance	-	-	-	-	-	-	-	X
OQIC 11*	CEA and Breast Cancer	-	-	-	-	-	-	-	X
OQIC 12*	GCSF: Utilization of GCSF in Metastatic Colon Cancer	-	-	-	-	-	-	-	X
OQIC 13	Appropriate Antiemetic Usage	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
QQIC 14 Appropriate Trastuzumab Use in Women with HER2/neu Gene Overexpression	-	-	-	-	-	-	-	X
QQIC 15 Metastatic Colon Cancer	-	-	-	-	-	-	-	X
QQIC 16 Appropriate Use of Late Line Chemotherapy in Metastatic Lung Cancer	-	-	-	-	-	-	-	X
QQIC 17 Intensity-Modulated Radiation Therapy (IMRT)	-	-	-	-	-	-	-	X
PInc 11 Aspirin at Arrival	-	-	-	-	-	-	-	X
PInc 12 Evaluation of LVS Function	-	-	-	-	-	-	-	X
QOPI 1 Staging Documented within One Month of First Office Visit	-	-	-	-	-	-	-	X
QOPI 7 Antiemetic Therapy Prescribed for Highly Emetogenic Chemotherapy	-	-	-	-	-	-	-	X
QOPI 8 Antiemetic Therapy Prescribed for Moderately Emetogenic Chemotherapy	-	-	-	-	-	-	-	X
QOPI 11 Combination Chemotherapy Received within 4 Months of Diagnosis by Women under 70 with AJCC Stage I (T1c) to III ER/PR Negative Breast Cancer	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
QOPI 12	Test for HER2/NEU Overexpression or Gene Amplification	-	-	-	-	-	-	-	X
QOPI 13	Trastuzumab Received by Patients with AJCC Stage I (T1c) to III HER2/NEU Positive Breast Cancer	-	-	-	-	-	-	-	X
QOPI 14	Tamoxifen or AI Received within 1 Year of Diagnosis by Patients with AJCC Stage I (T1c) to III ER/PR Positive Breast Cancer	-	-	-	-	-	-	-	X
QOPI 16	Adjuvant Chemotherapy Received within 4 Months of Diagnosis by Patients with AJCC Stage III Colon Cancer	-	-	-	-	-	-	-	X
QOPI 17	Location of Death Documented (*Paired Measure)	-	-	-	-	-	-	-	X
RPAQIR 1	Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy	-	-	-	-	-	-	-	X
RPAQIR 2	Adequacy of Volume Management	-	-	-	-	-	-	-	X
RPAQIR 3*	ESRD Patients Receiving Dialysis: Hemoglobin Level < 10g/dL	-	-	-	-	-	-	-	X
RPAQIR 4	Arteriovenous Fistula Rate	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
VAN 4 Preventive Care and Screening: Cholesterol—Fasting Low Density Lipoprotein (LDL-C) Test Performed	-	-	-	-	-	-	-	-	X
VAN 5 Cervical Cancer Screening	-	-	-	-	-	-	-	-	X
VAN 6 Hemoglobin A1c Test for Pediatric Patients	-	-	-	-	-	-	-	-	X
WCHQ 1 Diabetes Care: A1C Blood Sugar Testing (Chronic Care)	-	-	-	-	-	-	-	-	X
WCHQ 2 Diabetes Care: A1C Blood Sugar Control (Chronic Care)	-	-	-	-	-	-	-	-	X
WCHQ 3 Diabetes Care: LDL Cholesterol Testing (Chronic Care)	-	-	-	-	-	-	-	-	X
WCHQ 4 Diabetes Care: LDL Cholesterol Control (Chronic Care)	-	-	-	-	-	-	-	-	X
WCHQ 5 Diabetes Care: Kidney Function Monitored (Chronic Care)	-	-	-	-	-	-	-	-	X
WCHQ 6 Diabetes Care: Blood Pressure Control (Chronic Care)	-	-	-	-	-	-	-	-	X
WCHQ 8 Diabetes Care: Daily Aspirin or Other Antiplatelet (Chronic Care)	-	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
WCHQ 9	Diabetes Care: All or None Process Measure—Optimal Testing (Chronic Care)	-	-	-	-	-	-	-	X
WCHQ 10	Diabetes Care - All or None Process Measure: Optimal Outcomes (Chronic Care)	-	-	-	-	-	-	-	X
WCHQ 11	Controlling High Blood Pressure: Blood Pressure Control (Chronic Care)	-	-	-	-	-	-	-	X
WCHQ 12	Ischemic Vascular Disease Care: Daily Aspirin or Other Antiplatelet Medication Usage (Chronic Care)	-	-	-	-	-	-	-	X
WCHQ 13	Ischemic Vascular Disease Care: Blood Pressure Control (Chronic Care)	-	-	-	-	-	-	-	X
WCHQ 14	Preventive Care: Adults with Pneumococcal Vaccinations (Preventive Care)	-	-	-	-	-	-	-	X
WCHQ 15	Preventive Care: Screening for Osteoporosis (Preventative Care)	-	-	-	-	-	-	-	X
WCHQ 18	Preventive Care: Breast Cancer Screening	-	-	-	-	-	-	-	X
WCHQ 19	Preventive Care: Cervical Cancer Screening	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
WCHQ 20	Preventive Care: Colorectal Cancer Screening	-	-	-	-	-	-	-	X
WCQIC 1	Chronic Wound Care: Assessment of Wound Characteristics in Patients Undergoing Debridement	-	-	-	-	-	-	-	X
WCQIC 3	Chronic Wound Care: Offloading (Pressure Relief) of Diabetic Foot Ulcers	-	-	-	-	-	-	-	X
WCQIC 5	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	-	-	-	-	-	-	-	X
WCQIC 7	Peripheral Artery Disease (PAD) Screening	-	-	-	-	-	-	-	X
<b>Person and Caregiver-Centered Experience and Outcomes</b>		-	-	-	-	-	-	-	-
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	91.33%	20.38%	X	X	-	-	-	X
109	Osteoarthritis (OA): Function and Pain Assessment	88.55%	22.80%	X	X	-	-	-	X
143 (CMS157v2)	Oncology: Medical and Radiation—Pain Intensity Quantified	81.00%	25.88%	-	X	X	X	-	X
144	Oncology: Medical and Radiation—Plan of Care for Pain	68.24%	30.22%	-	X	-	X	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	74.58%	40.39%	-	X	-	X	-	X
342	Pain Brought Under Control within 48 Hours	-	-	-	X	-	-	-	X
358	Patient-Centered Surgical Risk Assessment and Communication	87.19%	27.15%	-	X	-	X	-	X
375 (CMS66v2)	Functional Status Assessment for Knee Replacement	-	-	-	-	X	-	-	X
376 (CMS56v2)	Functional Status Assessment for Hip Replacement	-	-	-	-	X	-	-	X
377 (CMS90v3)	Functional Status Assessment for Complex Chronic Conditions	-	-	-	-	X	-	-	X
AAAAI 10	Documentation of the Consent Process for Subcutaneous Allergy Immunotherapy in the Medical Record	-	-	-	-	-	-	-	X
AAAAI 14	Patient Self-Management Plan	-	-	-	-	-	-	-	X
AAAAI 16	Optimal Asthma Care: Control Component	-	-	-	-	-	-	-	X
AGADHRPR 8	Sustained Virological Response (SVR) (Quality Improvement Only)	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
AQI 2 Prevention of Post-Operative Nausea and Vomiting (PONV)—Combination Therapy (Adults)	-	-	-	-	-	-	-	-	X
AQI 3 Prevention of Post-Operative Vomiting (POV)—Combination Therapy (Pediatrics)	-	-	-	-	-	-	-	-	X
AQI 9 Short-Term Pain Management	-	-	-	-	-	-	-	-	X
AQI 11 Composite Patient Experience Measure	-	-	-	-	-	-	-	-	X
ASBS 2* Surgical Site Infection and Cellulitis After Breast and/or Axillary Surgery	-	-	-	-	-	-	-	-	X
CDR 2* Outcome Measure: Diabetic Foot Ulcer (DFU) Healing or Closure	-	-	-	-	-	-	-	-	X
CDR 6* Venous Leg Ulcer Outcome Measure: Healing or Closure	-	-	-	-	-	-	-	-	X
CDR 12 Patient Reported Experience of Care: Wound Related Quality of Life	-	-	-	-	-	-	-	-	X
CUHSM 3 CAHPS Clinician/Group Surveys—(Adult Primary Care, Pediatric Care, and Specialist Care Surveys)	-	-	-	-	-	-	-	-	X
CUHSM 4 CAHPS Health Plan Survey v4.0—Adult Questionnaire	-	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
ICLOPS 4 Patients Admitted to ICU Who Have Care Preferences Documented	-	-	-	-	-	-	-	-	X
ICLOPS 10 Hospice and Palliative Care—Treatment Preferences	-	-	-	-	-	-	-	-	X
ICLOPS 11 Percentage of Hospice Patients with Documentation in the Clinical Record of a Discussion of Spiritual/Religious Concerns or Documentation that the Patient/Caregiver Did Not Want to Discuss	-	-	-	-	-	-	-	-	X
ICLOPS 18 CG-CAHPS Clinician/Group Survey	-	-	-	-	-	-	-	-	X
OBERD 3 Back Pain: Shared Decision Making	-	-	-	-	-	-	-	-	X
OBERD 8 Orthopedic Pain: Shared Decision Making	-	-	-	-	-	-	-	-	X
OBERD 12 CG-CAHPS Adult Visit Composite Tracking	-	-	-	-	-	-	-	-	X
OQIC 1* Hospital Emergency Room Chemotherapy Related Visits	-	-	-	-	-	-	-	-	X
OQIC 2* Hospital Admissions Related to Complications of Chemotherapy	-	-	-	-	-	-	-	-	X
OQIC 4 Advance Care Planning in Stage 4 Disease	-	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
QOIC 5*	Chemotherapy in the Last Two Weeks of Life	-	-	-	-	-	-	-	X
QOIC 6*	In Hospital Deaths	-	-	-	-	-	-	-	X
QOIC 7*	In ICU Deaths	-	-	-	-	-	-	-	X
QOIC 9*	Hospice Admission Rate for Patients Dying with a Cancer Diagnosis	-	-	-	-	-	-	-	X
ONSQIR 10	Post-Treatment Goal Setting	-	-	-	-	-	-	-	X
ONSQIR 11	Post-Treatment Goal Attainment	-	-	-	-	-	-	-	X
ONSQIR 13*	Fatigue Improvement	-	-	-	-	-	-	-	X
ONSQIR 14	Psychosocial Distress Improvement	-	-	-	-	-	-	-	X
QOPI 2	Pain Intensity Quantified by Second Office Visit	-	-	-	-	-	-	-	X
QOPI 3	Chemotherapy Intent Documented	-	-	-	-	-	-	-	X
QOPI 9	Pain Intensity Quantified on Either of the Last Two Visits before Death	-	-	-	-	-	-	-	X
QOPI 10	Hospice Enrollment and Enrolled More than 3 Days before Death	-	-	-	-	-	-	-	X
QOPI 18	Death from Cancer in Intensive Care Unit (*Paired Measure)	-	-	-	-	-	-	-	X
QOPI 19*	Chemotherapy Administered within Last 2 Weeks of Life	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	QCDR
QOPI 20	Documentation of Patient's Advance Directives by the Third Office Visit	-	-	-	-	-	-	-	X
RPAQIR 6	Advance Care Planning	-	-	-	-	-	-	-	X
RPAQIR 7	Advance Directives Completed	-	-	-	-	-	-	-	X
RPAQIR 9	Advance Care Planning (Pediatric Kidney Disease)	-	-	-	-	-	-	-	X
VAN 7	CG-CAHPS Clinician / Group Survey	-	-	-	-	-	-	-	X
WCQIC 2	Chronic Wound Care: Patient Education Regarding Diabetic Foot Care	-	-	-	-	-	-	-	X
WCQIC 4	Chronic Wound Care: Patient Education Regarding Long Term Compression Therapy	-	-	-	-	-	-	-	X
WCQIC 6	Effective Use of Biologic Dressings	-	-	-	-	-	-	-	X
<b>Community/Population Health</b>		-	-	-	-	-	-	-	-
110 (GPRO PREV-7, CMS147v2)	Preventive Care and Screening: Influenza Immunization	47.75%	31.17%	X	X	X	X	X	X
128 (GPRO PREV-9, CMS69v2)	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	63.92%	26.74%	X	X	X	X	X	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
131	Pain Assessment and Follow-Up	83.76%	32.43%	X	X	-	-	-	X
134 (GPRO PREV-12, CMS2v3)	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	30.53%	36.75%	X	X	X	-	X	X
173	Preventive Care and Screening: Unhealthy Alcohol Use—Screening	64.37%	31.98%	-	X	-	X	-	X
183	Hepatitis C: Hepatitis A Vaccination in Patients with Hepatitis C Virus (HCV)	37.24%	30.95%	-	X	-	X	-	X
226 (GPRO PREV-10, CMS138v2)	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	89.05%	19.51%	X	X	X	X	X	X
239 (CMS155v2)	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	-	-	-	-	X	-	-	X
240 (CMS117v2)	Childhood Immunization Status	-	-	-	-	X	-	-	X
310 (CMS153v2)	Chlamydia Screening for Women	-	-	-	-	X	-	-	X
317 (GPRO PREV-11, CMS22v2)	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	57.52%	35.43%	X	X	X	X	X	X
372 (CMS82v1)	Maternal Depression Screening	-	-	-	-	X	-	-	X
AAAAI 3	Asthma: Tobacco Use: Screening	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	QCDR
AAAAI 4	Asthma: Tobacco Use: Intervention	-	-	-	-	-	-	-	X
AAAAI 13	Influenza Immunization	-	-	-	-	-	-	-	X
AAAAI 15	Body Mass Index	-	-	-	-	-	-	-	X
ACCFocus 7*	Disparities in Appropriate Patient Selection for Cardiac Imaging between Men and Women	-	-	-	-	-	-	-	X
ACCFocus 8*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria in Patients Less than 50 Years Old	-	-	-	-	-	-	-	X
QOPI 6	Smoking Status/Tobacco Use Documented in Past Year	-	-	-	-	-	-	-	X
VAN 2	Childhood Immunization Status	-	-	-	-	-	-	-	X
VAN 3	Chlamydia Screening for Women	-	-	-	-	-	-	-	X
WCHQ 7	Diabetes Care - Tobacco Free (Chronic Care)	-	-	-	-	-	-	-	X
WCHQ 16	Adult Tobacco Use: Screening for Tobacco Use (Preventive Care)	-	-	-	-	-	-	-	X
WCHQ 17	Adult Tobacco Use: Screening for Tobacco Use (Preventive Care)	-	-	-	-	-	-	-	X
<b>Patient Safety</b>		-	-	-	-	-	-	-	-
20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic— Ordering Physician	93.18%	17.15%	X	X	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
21	Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin	87.81%	25.24%	X	X	-	X	-	X
22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)	84.59%	27.72%	X	X	-	X	-	X
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	91.41%	23.08%	X	X	-	X	-	X
30	Perioperative Care: Timing of Prophylactic Antibiotic—Administering Physician	95.42%	9.50%	X	X	-	-	-	X
45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)	96.26%	12.56%	X	X	-	-	-	X
46 (GPRO CARE-1)	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	84.39%	23.75%	X	X	-	-	X	X
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	84.21%	24.20%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
130 (CMS68v3)	Documentation of Current Medications in the Medical Record	83.63%	25.28%	X	X	X	X	-	X
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	77.92%	25.04%	X	X	-	-	-	X
154	Falls: Risk Assessment	38.78%	42.85%	X	X	-	-	-	X
156	Oncology: Radiation Dose Limits to Normal Tissues	97.75%	7.63%	X	X	-	-	-	X
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	-	-	X	X	-	-	-	X
181	Elder Maltreatment Screen and Follow-Up Plan	36.87%	46.94%	X	X	-	-	-	X
192* (CMS132v2)	Cataracts: Complications Within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	2.03%	10.24%	-	X	X	X	-	X
193	Perioperative Temperature Management	93.11%	11.37%	X	X	-	-	-	X
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy or Formal Segmentectomy)	-	-	-	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
238* (CMS156v2) Use of High-Risk Medications in the Elderly	-	-	-	-	X	-	-	X
262 Image Confirmation of Successful Excision of Image-Localized Breast Lesion	-	-	X	X	-	-	-	X
286 Dementia: Counseling Regarding Safety Concerns	90.76%	18.27%	-	-	-	X	-	X
318 (GPRO CARE-2, CMS139v2) Falls: Screening for Future Fall Risk	47.27%	26.41%	-	-	X	-	X	X
326 Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	71.65%	32.46%	X	X	-	-	-	X
335 Maternity Care: Elective Delivery or Early Induction Without Medical Indication at ≥ 37 and < 39 Weeks	-	-	-	X	-	-	-	X
351 Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation	93.74%	18.62%	-	-	-	X	-	X
352 Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet	97.54%	12.91%	-	-	-	X	-	X
353 Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report	94.22%	17.66%	-	-	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
360 Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies	-	-	-	-	-	X	-	X	
361 Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry	-	-	-	-	-	X	-	X	
380 (CMS179v2) ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range	-	-	-	-	X	-	-	X	
382 (CMS177v2) Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment	-	-	-	-	X	-	-	X	
AAAAI 5 Allergy Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment	-	-	-	-	-	-	-	X	
AAAAI 9 Assessment of Asthma Symptoms Prior to Administration of Allergy Immunotherapy Injection(s)	-	-	-	-	-	-	-	X	
ACR 4 Tuberculosis (TB) Test Prior to First Course Biologic Therapy	-	-	-	-	-	-	-	X	

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
ACRad 9*	Median Dose Length Product for CT Head/Brain without Contrast (Single Phase Scan)	-	-	-	-	-	-	-	X
ACRad 10*	Median Size Specific Dose Estimate for CT Chest without Contrast (Single Phase Scan)	-	-	-	-	-	-	-	X
ACRad 11*	Median Dose Length Product for CT Chest without Contrast (Single Phase Scan)	-	-	-	-	-	-	-	X
ACRad 12*	Median Size Specific Dose Estimate for CT Abdomen-Pelvis with Contrast (Single Phase Scan)	-	-	-	-	-	-	-	X
ACRad 13*	Median Dose Length Product for CT Abdomen-Pelvis with Contrast (Single Phase Scan)	-	-	-	-	-	-	-	X
ACRad 14	Participation in a National Dose Index Registry	-	-	-	-	-	-	-	X
ACRad 20*	CT IV Contrast Extravasation Rate (Low Osmolar Contrast Media)	-	-	-	-	-	-	-	X
AGACCSSR 1	Colonoscopy Assessment (Procedure Adequacy) - Assessment of Bowel Preparation	-	-	-	-	-	-	-	X
AGACCSSR 3*	Hospital Visit Rate After Outpatient Colonoscopy	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
AGADHRPR 1*	Colonoscopy Assessment (Procedure Adequacy) - Assessment of Bowel Preparation	-	-	-	-	-	-	-	X
AGADHRPR 3*	Hospital Visit Rate After Outpatient Colonoscopy	-	-	-	-	-	-	-	X
AGADHRPR 6	Hepatitis B Vaccination in Patients with HCV	-	-	-	-	-	-	-	X
AGADHRPR 7	Discontinuation of Antiviral Therapy for Inadequate Viral Response	-	-	-	-	-	-	-	X
AGADHRPR 9	One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk	-	-	-	-	-	-	-	X
AGADHRPR 10	Screening for Hepatocellular Carcinoma (HCC) in Patients with Hepatitis C Cirrhosis	-	-	-	-	-	-	-	X
ASBS 4	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic—Ordering Physician	-	-	-	-	-	-	-	X
ASBS 5	Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin	-	-	-	-	-	-	-	X
ASBS 6	Perioperative Care: Discontinuation of Prophylactic Antibiotic	-	-	-	-	-	-	-	X
AQI 6	Immediate Perioperative Cardiac Arrest Rate	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
AQI 7	Immediate Perioperative Mortality Rate	-	-	-	-	-	-	-	X
AQI 8	PACU Reintubation Rate	-	-	-	-	-	-	-	X
AQI 10	Composite Procedural Safety for Central Line Placement	-	-	-	-	-	-	-	X
GIQIC 5*	Incidence of Perforation	-	-	-	-	-	-	-	X
ICLOPS 3	Hospitalized Patients Who Die an Expected Death with an ICD that Has Been Deactivated	-	-	-	-	-	-	-	X
MBSAQIP 8*	Risk Standardized Rate of Patients Who Experienced Extended Length of Stay (> 7 Days) Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	X
MBS 1*	Medical Complications	-	-	-	-	-	-	-	X
MBS 2*	Surgical Site Complications	-	-	-	-	-	-	-	X
MBS 3*	Serious Complications	-	-	-	-	-	-	-	X
MUSIC 1	Prostate Biopsy: Compliance with AUA Best Practices for Antibiotic Prophylaxis for Transrectal Ultrasound-Guided (TRUS) Biopsy	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
Plnc 4*	30 Day Mortality for Acute Myocardial Infarction	-	-	-	-	-	-	-	X
Plnc 5*	30 Day Mortality for Heart Failure	-	-	-	-	-	-	-	X
Plnc 6*	30 Day Mortality for Pneumonia	-	-	-	-	-	-	-	X
Plnc 7	Venous Thromboembolism (VTE) Prophylaxis	-	-	-	-	-	-	-	X
Plnc 10	Elective Delivery	-	-	-	-	-	-	-	X
Plnc 14	Prophylactic Antibiotic Received within 1 Hour Prior to Surgical Incision	-	-	-	-	-	-	-	X
Plnc 15	Prophylactic Antibiotic Selection for Surgical Patients	-	-	-	-	-	-	-	X
Plnc 16	Prophylactic Antibiotics Discontinued within 24 Hours after Surgery End (48 Hours for CABG/Other Cardiac Surgery)	-	-	-	-	-	-	-	X
Plnc 17	Surgery Patients on Beta Blocker Therapy Who Receive a Beta Blocker during the Perioperative Period	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	QCDR
PInc 18	Surgery Patients Who Received Appropriate Venous Thromboembolism Prophylaxis within 24 Hours Prior to Surgery up to 24 Hours After Surgery End Time	-	-	-	-	-	-	-	X
PInc 19	Antibiotic Timing	-	-	-	-	-	-	-	X
PInc 20	Antibiotic Selection	-	-	-	-	-	-	-	X
VAN 1*	Use of High-Risk Medications in the Elderly	-	-	-	-	-	-	-	X
<b>Communication and Care Coordination</b>		-	-	-	-	-	-	-	
24	Osteoporosis: Communication with the Physician Managing Ongoing Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	62.39%	41.92%	X	X	-	-	-	X
47	Advance Care Plan	57.82%	36.99%	X	X	-	-	-	X
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	94.82%	4.63%	-	X	-	-	-	X
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	-	-	-	X	-	-	-	X
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy— Avoidance of Inappropriate Use	87.92%	18.40%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
138	Melanoma: Coordination of Care	88.36%	7.80%	-	X	-	-	-	X
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	97.11%	11.28%	X	X	-	-	-	X
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	73.72%	23.30%	X	X	-	-	-	X
155	Falls: Plan of Care	74.91%	36.08%	X	X	-	-	-	X
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	97.73%	10.15%	-	X	-	X	-	X
182	Functional Outcome Assessment	94.96%	16.23%	X	X	-	-	-	X
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use	93.93%	15.08%	X	X	-	-	-	X
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	82.64%	15.69%	-	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
218 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	85.41%	14.41%	-	X	-	-	-	X
219 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	82.24%	17.07%	-	X	-	-	-	X
220 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	78.10%	19.21%	-	X	-	-	-	X
221 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	83.14%	14.26%	-	X	-	-	-	X
222 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	-	-	-	X	-	-	-	X
223 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs or Other General Orthopedic Impairments	77.74%	19.02%	-	X	-	-	-	X
225 Radiology: Reminder System for Mammograms	88.34%	24.60%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
258	-	-	-	X	-	-	-	X
259	-	-	-	X	-	-	-	X
260	-	-	-	X	-	-	-	X
261	80.88%	27.69%	X	X	-	-	-	X
265	81.90%	32.67%	-	X	-	-	-	X
280	91.50%	16.66%	-	-	-	X	-	X
320	83.55%	23.80%	X	X	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
336 Maternity Care: Post-Partum Follow-Up and Care Coordination	-	-	-	X	-	-	-	X
350 Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-Surgical) Therapy	96.97%	10.82%	-	-	-	X	-	X
359 Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computerized Tomography (CT) Imaging Description	-	-	-	-	-	X	-	X
362 Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-Up and Comparison Purposes	-	-	-	-	-	X	-	X
363 Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Imaging Studies Through a Secure, Authorized, Media-Free, Shared Archive	-	-	-	-	-	X	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
364 Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-Up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines	-	-	-	-	-	X	-	X	
374 (CMS50v2) Closing the Referral Loop: Receipt of Specialist Report	-	-	-	-	X	-	-	X	
AAAAI 6 Documentation of Clinical Response to Allergy Immunotherapy within One Year	-	-	-	-	-	-	-	X	
ACRad 15* Report Turnaround Time: Radiography	-	-	-	-	-	-	-	X	
ACRad 16* Report Turnaround Time: Ultrasound (Excluding Breast US)	-	-	-	-	-	-	-	X	
ACRad 17* Report Turnaround Time: MRI	-	-	-	-	-	-	-	X	
ACRad 18* Report Turnaround Time: CT	-	-	-	-	-	-	-	X	
ACRad 19* Report Turnaround Time: PET	-	-	-	-	-	-	-	X	
ASBS 3 Specimen Orientation for Partial Mastectomy or Excisional Breast Biopsy	-	-	-	-	-	-	-	X	

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
AQI 1	Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU)	-	-	-	-	-	-	-	X
AQI 4	Anesthesiology: Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit	-	-	-	-	-	-	-	X
CDR 3	Process Measure: Plan of Care Creation for Diabetic Foot Ulcer (DFU) Patients Not Achieving 30% Closure at 4 Weeks	-	-	-	-	-	-	-	X
CDR 7	Process Measure: Plan of Care for Venous Leg Ulcer Patients Not Achieving 30% Closure at 4 Weeks	-	-	-	-	-	-	-	X
CUHSM 1	Adherence to Statins	-	-	-	-	-	-	-	X
CUHSM 2	5 Rates by Therapeutic Category: Proportion of Days Covered (PDC)	-	-	-	-	-	-	-	X
CUHSM 5	Care for Older Adults (COA)—Medication Review	-	-	-	-	-	-	-	X
GIQIC 6	Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Reporting Options							QCDR
		2014 Mean	2014 Standard Deviation	Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
GIQIC 10	Appropriate Management of Anticoagulation in the Periprocedural Period Rate—EGD	-	-	-	-	-	-	-	X
GIQIC 11	<i>Helicobacter pylori</i> ( <i>H. pylori</i> ) Status Rate	-	-	-	-	-	-	-	X
GIQIC 13	Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use	-	-	-	-	-	-	-	X
ICLOPS 1	Comfortable Dying: Pain Brought to a Comfortable Level Within 48 Hours of Initial Assessment	-	-	-	-	-	-	-	X
ICLOPS 2	Patients Treated with an Opioid Who Are Given a Bowel Regimen	-	-	-	-	-	-	-	X
ICLOPS 5	Patients with Advanced Cancer Screened for Pain at Outpatient Visits	-	-	-	-	-	-	-	X
ICLOPS 6	Hospice and Palliative Care—Pain Screening	-	-	-	-	-	-	-	X
ICLOPS 7	Hospice and Palliative Care—Pain Assessment	-	-	-	-	-	-	-	X
ICLOPS 8	Hospice and Palliative Care—Dyspnea Treatment	-	-	-	-	-	-	-	X
ICLOPS 9	Hospice and Palliative Care—Dyspnea Screening	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
ICLOPS 17 Rate of Follow Up Visits within 7 Days of Discharge (and Physician Response)	-	-	-	-	-	-	-	X
MBSAQIP 9 Percentage of Patients Who Had Complete 30 Day Follow-Up Following Any Metabolic and Bariatric Procedure	-	-	-	-	-	-	-	X
NOF 2 Risk Assessment/Treatment After Fracture	-	-	-	-	-	-	-	X
NOF 3 Discharge Instructions: Emergency Department	-	-	-	-	-	-	-	X
OBERD 1 Back Pain: Mental Health Assessment	-	-	-	-	-	-	-	X
OBERD 2 Back Pain: Patient Reassessment	-	-	-	-	-	-	-	X
OBERD 4 Pain Assessment and Follow-Up	-	-	-	-	-	-	-	X
OBERD 5* Back Pain: Surgical Timing	-	-	-	-	-	-	-	X
OBERD 6 Orthopedic Pain: Mental Health Assessment	-	-	-	-	-	-	-	X
OBERD 7 Orthopedic Pain: Patient Reassessment	-	-	-	-	-	-	-	X
OBERD 9 Orthopedic Pain: Assessment and Follow-Up	-	-	-	-	-	-	-	X
OBERD 10 Quality of Life (VR-12 or Promis Global 10) Monitoring	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
OBERD 11	Quality of Life (VR-12 or Promis Global 10) Outcomes	-	-	-	-	-	-	-	X
OBERD 13*	Orthopedic Functional and Pain Level Outcomes	-	-	-	-	-	-	-	X
ONSQIR 12	Post-Treatment Follow Up Care	-	-	-	-	-	-	-	X
Plnc 1*	30 Day Readmission for Acute Myocardial Infarction	-	-	-	-	-	-	-	X
Plnc 2*	30 Day Readmission for Heart Failure	-	-	-	-	-	-	-	X
Plnc 3*	30 Day Readmission for Pneumonia	-	-	-	-	-	-	-	X
Plnc 8	Discharged on Antithrombotic Therapy	-	-	-	-	-	-	-	X
Plnc 9	Anticoagulation Therapy for Atrial Fibrillation/Flutter	-	-	-	-	-	-	-	X
Plnc 13	Initial Antibiotic Selection for CAP Immunocompetent Patients	-	-	-	-	-	-	-	X
RPAQIR 5	Transplant Referral	-	-	-	-	-	-	-	X
RPAQIR 8	Referral to Hospice	-	-	-	-	-	-	-	X
<b>Efficiency and Cost Reduction</b>		-	-	-	-	-	-	-	
65 (CMS154v2)	Appropriate Treatment for Children with Upper Respiratory Infection (URI)	-	-	-	X	X	-	-	X
66 (CMS146v2)	Appropriate Testing for Children with Pharyngitis	-	-	-	X	X	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCQR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
102 (CMS129v3)	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	93.57%	15.37%	X	X	X	-	-	X
116	Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis	-	-	-	X	-	-	-	X
146*	Radiology: Inappropriate Use of 'Probably Benign' Assessment Category in Mammography Screening	0.49%	4.15%	X	X	-	-	-	X
148	Back Pain: Initial Visit	83.45%	29.21%	-	-	-	X	-	X
224	Melanoma: Overutilization of Imaging Studies in Melanoma	99.60%	3.19%	-	X	-	-	-	X
312 (CMS166v3)	Low Back Pain: Use of Imaging Studies	-	-	-	-	X	-	-	X
322*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	-	-	-	X	-	-	-	X
323*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	4.07%	16.27%	-	X	-	-	-	X
324*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients	2.99%	6.19%	-	X	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
333*	Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)	4.59%	6.07%	-	X	-	-	-	X
334*	Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)	1.49%	3.90%	-	X	-	-	-	X
340	HIV Medical Visit Frequency	86.43%	18.81%	-	-	-	X	-	-
341*	Gap in HIV Medical Visits	7.43%	9.71%	-	-	-	X	-	-
AAAAI 7	Documented Rationale to Support Long-Term Aeroallergen Immunotherapy Beyond Five Years, As Indicated	-	-	-	-	-	-	-	X
ACCFocus 1*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Asymptomatic, Low Risk Patients	-	-	-	-	-	-	-	X
ACCFocus 2*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Symptomatic, Low Pre-Test Probability Patients Who Can Exercise and Have an Interpretable ECG	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
ACCFocus 3*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Low Risk Surgery Preoperative Testing	-	-	-	-	-	-	-	X
ACCFocus 4*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing after Percutaneous Coronary Intervention (PCI)	-	-	-	-	-	-	-	X
ACCFocus 5*	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Surveillance Testing after an Interpretable Prior SPECT MPI or Stress Echo in Asymptomatic Patients	-	-	-	-	-	-	-	X
ACCFocus 6*	Ratio: Rarely Appropriate Tests Ordered Per Physician Compared to the National Average	-	-	-	-	-	-	-	X
ACRad 2	CT Colonography Clinically Significant Extracolonic Findings	-	-	-	-	-	-	-	X
ACRad 5*	Screening Mammography Abnormal Interpretation Rate (Recall Rate)	-	-	-	-	-	-	-	X
AGACCSSR 4	Performance of Upper Endoscopic Examination with Colonoscopy	-	-	-	-	-	-	-	X
AGACCSSR 5*	Unnecessary Screening Colonoscopy in Older Adults	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					GPRO Web Interface/ACO	QCDR
			Claims	Registry	EHR	Measures Group			
AGADHRPR 4	-	-	-	-	-	-	-	-	X
AGADHRPR 5*	-	-	-	-	-	-	-	-	X
GIQIC 7	-	-	-	-	-	-	-	-	X
GIQIC 8*	-	-	-	-	-	-	-	-	X
GIQIC 12	-	-	-	-	-	-	-	-	X
ICLOPS 15	-	-	-	-	-	-	-	-	X
ICLOPS 16	-	-	-	-	-	-	-	-	X
MBSAQIP 2*	-	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name	2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
			Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
MBSAQIP 3* Risk Standardized Rate of Patients Who Experienced a Reoperation (Likely Related to the Initial Operation) within 30 days Following a Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy Operation, Performed as a Primary (Not Revisional) Procedure	-	-	-	-	-	-	-	X
MBS 7* Extended Length of Stay (LOS)	-	-	-	-	-	-	-	X
MBS 8* Unplanned Emergency Room (ER) visits	-	-	-	-	-	-	-	X
MBS 9* Unplanned Hospital Readmission within 30 Days of Principal Procedure	-	-	-	-	-	-	-	X
MUSIC 3 Prostate Cancer: Avoidance of Overuse of CT Scan for Staging Low Risk Prostate Cancer Patients	-	-	-	-	-	-	-	X
OQIC 3* Hospital Days	-	-	-	-	-	-	-	X
OQIC 8* Hospital Days	-	-	-	-	-	-	-	X
QOPI 4 Performance Status Documented Prior to Initiating Non-Curative Chemotherapy Regimen	-	-	-	-	-	-	-	X

2014 PQRS Measure Number and Measure Name		2014 Mean	2014 Standard Deviation	2014 Reporting Options					QCDR
				Claims	Registry	EHR	Measures Group	GPRO Web Interface/ACO	
QOPI 5*	Chemotherapy Administered to Patients with Metastatic Solid Tumors and Performance Status of 3, 4, or Undocumented (Lower Score Better)	-	-	-	-	-	-	-	X
QOPI 15*	GCSF Administered to Patients Who Received Chemotherapy for Metastatic Cancer (Lower Score Better)	-	-	-	-	-	-	-	X
STS 1*	CABG - Prolonged Length of Stay	-	-	-	-	-	-	-	X
STS 2	CABG - Short Length of Stay	-	-	-	-	-	-	-	X
STS 3*	CABG + Valve Prolonged Length of Stay	-	-	-	-	-	-	-	X
STS 4	CABG + Valve Short Length of Stay	-	-	-	-	-	-	-	X
STS 5*	Valve - Prolonged Length of Stay	-	-	-	-	-	-	-	X
STS 6	Valve - Short Length of Stay	-	-	-	-	-	-	-	X

Note: This table presents means, standard deviations, and reporting options for 2014 PQRS measures. Not all benchmarks will be applicable to 2015 performance, depending on whether a comparable measure exists in 2015. Benchmarks are not available for measures where fewer than twenty groups reported at least twenty cases. Benchmarks for measures that could only be reported in 2014 via the qualified clinical data registry (QCDR) or electronic health record (EHR) reporting options are suppressed because we are unable to determine the accuracy of these data. Benchmarks for PQRS #112 and #238 are not reported, due to technical errors in the specifications of these measures.

\* Lower performance rates on this measure indicate better performance.

**Consumer Assessment of Healthcare Providers and Systems (CAHPS) for PQRS Measures**

PQRS Measure Name	2014 Mean	2014 Standard Deviation
Getting Timely Care	80.46	4.31
Provider Communication	92.82	1.65
Rating of Provider	91.80	1.65
Access to Specialists	84.28	2.62
Health Promotion and Education	59.01	4.47
Shared Decision-Making	75.03	2.40
Health Status/Functional Status	70.13	2.58
Courteous/Helpful Office Staff	92.23	2.54
Care Coordination	87.45	2.19
Between Visit Communication	59.13	7.15
Education About Medication Adherence	76.05	2.42
Stewardship of Patient Resources	26.88	5.00

Note: The CAHPS for PQRS survey measures are scored on a 0 to 100 point scale. Data on the "Health Status/Functional Status" measure, a descriptive measure of patient characteristics, is being provided to TINs for their information only. This measure will not be used in the calculation of the 2017 Value Modifier.

**Benchmarking and Measure Calculation Methodology**

- Benchmark means were computed as the case-weighted average of 2014 performance rates computed across all groups and solo practitioners (identified by Tax Identification Number, or TIN) meeting a specified minimum case threshold.
  - For each measure, each TIN's weight was the number of cases for the TIN divided by the total number of cases for the measure.
  - The case-weighted mean was computed by multiplying the performance rate for each TIN by its weight and then summing all terms.
  - For PQRS measures, performance rates for groups and eligible professionals (EPs) who avoided the 2016 PQRS payment adjustment were combined across reporting options.
  - PQRS data submitted through the qualified clinical data registry or electronic health record reporting options were not used in quality benchmarks because CMS was unable to determine the accuracy of these data.
  - For all measures except the all-cause hospital readmissions measure, the minimum case threshold was 20 cases, and benchmarks were not computed if fewer than twenty TINs reported at least twenty cases. For the all-cause hospital readmissions measure, the minimum case threshold was 200 cases for non-MSSP ACO TINs; no minimum case threshold applied for MSSP ACOs for this measure.
- Performance rates for the ambulatory care sensitive condition measures were computed:
  - Using 2014 measure specifications. Measure Information Forms can be found at <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/valuebasedpaymentmodifier.html>.
  - For all TINs with at least one physician
- Performance rates for the all-cause hospital readmissions measure were computed:
  - Using 2014 measure specifications. Measure Information Forms can be found at <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/valuebasedpaymentmodifier.html>.
  - For all TINs with at least one physician and with 10 or more eligible professionals<sup>1</sup>
  - For MSSP ACOs, the performance of the MSSP ACO (rather than the individual performance of each TIN) was used in the all-cause hospital readmissions benchmark; performance rates were weighted by the number of cases for the MSSP ACO on the measure divided by the total number of cases for the measure.

---

<sup>1</sup> The performance of TINs with fewer than 10 eligible professionals is excluded from the all-cause hospital readmissions benchmark because, under the 2017 Value Modifier, the all-cause hospital readmissions measure will only be included in the Quality Composite for TINs with at least 10 eligible professionals.

- PQRS performance rates reported by individual EPs were rolled up to the TIN level prior to computing benchmarks.
  - Only performance rates for EPs who avoided the 2016 PQRS payment adjustment were included.
  - For a given measure, all available submission mechanisms (excluding qualified clinical data registry and electronic health record mechanisms) were included.
  - If an EP within a TIN reported a performance rate for a measure more than once (under one or more reporting mechanisms), then a case-weighted average performance rate was computed for the EP over all submissions of the measure.
  - For each TIN and measure, rates were rolled up to the TIN level as follows:
    - For each EP within the TIN, the EP's performance rate was multiplied by the EP's denominator cases. The TIN numerator was then calculated as the sum of these EP-level products across all EPs within the TIN who reported the measure and avoided the 2016 PQRS payment adjustment.
    - The TIN denominator was calculated as the sum of the denominator cases across all EPs within the TIN who reported the measure and avoided the 2016 PQRS payment adjustment.
    - Each TIN's performance rate on the measure was calculated as the TIN numerator divided by the TIN denominator, multiplied by 100.